SUPERSTRING CAPITAL MANAGEMENT LP Portfolio
Auto-discovered active 13F filer.
SEC 13F CIK: 0001931118
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q4 2025 · 45 positions · Total reported value $186.78M · Top-10 concentration 57.8% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 65.1% · 8 new · 9 cut · 11 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q1 2026 → Q2 2026): +26.6% · vs SPY +11.8% · Prev Value $139.97M — last quarter positions weighted by this quarter price moves · ranking
In its Q4 2025 13F filing, SUPERSTRING CAPITAL MANAGEMENT LP disclosed 45 equity positions with a combined reported value of $186.78M. The filing implies a moderately concentrated portfolio: its ten largest positions account for 57.8% of reported value. HoldingsHub classifies the profile as Small / Health Tilt / High Turnover.
The largest disclosed positions as of Q4 2025 were CDTX ($18.80M), TERN ($17.93M), URGN ($16.82M). By sector, the heaviest allocations are Health Care 70.3%, Other 29.7%. Versus the prior quarter, allocation shifted toward Other (+11.0pp) and away from Health Care (-11.0pp).
Versus the prior quarter, SUPERSTRING CAPITAL MANAGEMENT LP opened 8 new positions, trimmed 9 and fully exited 11, a turnover rate of 65.1% of positions. The portfolio's overlap with the prior quarter was 25% of names.
The largest new positions opened in Q4 2025 were DVAX ($8.08M), SION ($7.43M), AXSM ($6.84M).
Of the 11 positions fully exited versus the prior quarter, the largest were ETNB ($5.65M), JAZZ ($5.39M), BBIO ($4.60M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q4 2025)
- DVAX DYNAVAX TECHNOLOGIES CORP · $8.08M
- SION SIONNA THERAPEUTICS INC COM · $7.43M
- AXSM AXSOME THERAPEUTICS INC. · $6.84M
- MNMD MIND MEDICINE MINDMED INC · $5.69M
- TSHA TAYSHA GENE THERAPIES IN · $5.39M
- OCUL OCULAR THERAPEUTIX INC · $5.08M
- FOLD AMICUS THERAPEUTICS INC · $5.03M
- UTHR UNITED THERAPEUTICS CORP DEL · $4.61M
Fully Exited (vs previous quarter)
- ETNB 89BIO INC · prev qtr: $5.65M
- JAZZ JAZZ PHARMACEUTICALS PLC · prev qtr: $5.39M
- BBIO BRIDGEBIO PHARMA INC · prev qtr: $4.60M
- SMMT SUMMIT THERAPEUTICS INC · prev qtr: $4.08M
- IQV IQVIA HLDGS INC · prev qtr: $3.63M
- REGN REGENERON PHARMACEUTICALS · prev qtr: $3.60M
- NKTR NEKTAR THERAPEUTICS · prev qtr: $2.92M
- INSM INSMED INC · prev qtr: $2.85M
Insider Transactions (Form 4)
Latest SUPERSTRING CAPITAL MANAGEMENT LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Superstring Capital Management, based in New York, NY, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 32 positions worth $158.38M in total. HoldingsHub carries 11 quarters of its filings (Q4 2023–Q2 2026).
Firm Snapshot
- Headquarters: NEW YORK, NY, United States
- SEC registration: 801-118766 (status: Approved), registered 2020-05-20
- Regulatory AUM (Form ADV): $339.50M as of 2026-03-30
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 2 private funds, of which 1 hedge funds
- Website: superstringcap.com
Portfolio Structure
- 32 positions · $158.38M reported value (Q2 2026)
- Top 10 holdings = 63.8% of reported value
- Largest position: COGT (COGENT BIOSCIENCES INC) at 8.4%
- Average position size: $4.95M
Sector Tilt
- Health Care 99.8%
- (classified holdings cover 100% of value)
Quarterly Activity
- Q2 2026: 8 new, 12 added, 9 reduced, 11 exited
- 3 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
85.10K | $18.80M | 10.06% | Add | |
| 2 |
|
443.78K | $17.93M | 9.60% | Reduce | |
| 3 |
|
718.35K | $16.82M | 9.01% | Add | |
| 4 |
|
366.24K | $13.01M | 6.96% | Add | |
| 5 |
|
525.59K | $8.08M | 4.33% | New | |
| 6 |
|
180.59K | $7.43M | 3.98% | New | |
| 7 |
|
288.68K | $7.34M | 3.93% | Reduce | |
| 8 |
|
37.43K | $6.84M | 3.66% | New | |
| 9 |
|
995.35K | $6.00M | 3.21% | Reduce | |
| 10 |
|
425.20K | $5.69M | 3.05% | New | |
| 11 |
|
980.77K | $5.39M | 2.89% | New | |
| 12 |
|
418.08K | $5.08M | 2.72% | New | |
| 13 |
|
352.90K | $5.03M | 2.69% | New | |
| 14 |
|
2.25M | $4.94M | 2.64% | Add | |
| 15 |
|
9.45K | $4.61M | 2.46% | New | |
| 16 |
|
54.88K | $4.37M | 2.34% | New | |
| 17 |
|
24.70K | $3.95M | 2.12% | New | |
| 18 |
|
47.28K | $3.69M | 1.98% | Reduce | |
| 19 |
|
196.85K | $3.47M | 1.86% | Reduce | |
| 20 |
|
83.35K | $3.03M | 1.62% | Reduce | |
| 21 |
|
858.71K | $2.88M | 1.54% | New | |
| 22 |
|
153.31K | $2.78M | 1.49% | Reduce | |
| 23 |
|
96.33K | $2.78M | 1.49% | New | |
| 24 |
|
25.47K | $2.67M | 1.43% | New | |
| 25 |
|
88.31K | $2.40M | 1.28% | New | |
| 26 |
|
65.27K | $2.22M | 1.19% | New | |
| 27 |
|
255.37K | $2.09M | 1.12% | Add | |
| 28 |
|
360.00K | $1.92M | 1.03% | Hold | |
| 29 |
|
148.29K | $1.86M | 0.99% | New | |
| 30 |
|
58.68K | $1.54M | 0.83% | New | |
| 31 |
|
38.02K | $1.45M | 0.78% | Reduce | |
| 32 |
|
43.23K | $1.35M | 0.72% | New | |
| 33 |
|
513.76K | $1.21M | 0.65% | New | |
| 34 |
|
26.25K | $1.08M | 0.58% | New | |
| 35 |
|
12.14K | $1.06M | 0.57% | New | |
| 36 |
|
69.50K | $912.13K | 0.49% | New | |
| 37 |
|
29.16K | $898.19K | 0.48% | New | |
| 38 |
|
367.10K | $862.69K | 0.46% | New | |
| 39 |
|
72.06K | $815.00K | 0.44% | New | |
| 40 |
|
31.74K | $729.97K | 0.39% | New | |
| 41 |
|
33.97K | $522.47K | 0.28% | New | |
| 42 |
|
100.00K | $465.00K | 0.25% | New | |
| 43 |
|
462.96K | $460.56K | 0.25% | Hold | |
| 44 |
|
250.00K | $310.00K | 0.17% | Hold | |
| 45 |
|
17.14K | $33.26K | 0.02% | New | |
FAQ
What did SUPERSTRING CAPITAL MANAGEMENT LP buy in 2025-Q4?
In its 2025-Q4 13F filing, SUPERSTRING CAPITAL MANAGEMENT LP reported 45 equity positions worth $186.78M in aggregate; its largest disclosed positions were CDTX ($18.80M), TERN ($17.93M), URGN ($16.82M).
How large is SUPERSTRING CAPITAL MANAGEMENT LP's portfolio?
SUPERSTRING CAPITAL MANAGEMENT LP reported $186.78M of long equity holdings across 45 positions as of 2025-Q4. Top-10 holdings account for 57.8% of reported value.
What is SUPERSTRING CAPITAL MANAGEMENT LP's investment style?
HoldingsHub classifies the portfolio as Small / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.